Cytokinetics Inc

+1.80 (+5.43%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.92B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.22 Million
Adjusted EPS-$0.78
See more estimates
10-Day MA$33.35
50-Day MA$31.31
200-Day MA$24.37
See more pivots

Cytokinetics Inc Stock, NASDAQ:CYTK

280 East Grand Avenue, South San Francisco, California 94080
Phone: +1.650.624.3000
Number of Employees: 184


Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.